Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

41. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 16554525 2006 03 23 2006 04 07 2015 11 19 1533-4406 354 12 2006 Mar 23 The New England journal of medicine N. Engl. J. Med. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 1231-42 After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. We (...) randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care

NEJM2006

42. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. 16820546 2006 07 05 2006 07 07 2016 10 17 1538-3598 296 1 2006 Jul 05 JAMA JAMA Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. 47-55 The alpha4beta2 nicotinic acetylcholine receptors (nAChRs (...) ) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were

JAMA2006

43. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. 16820547 2006 07 05 2006 07 07 2016 10 17 1538-3598 296 1 2006 Jul 05 JAMA JAMA Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. 56-63 Varenicline, a partial agonist (...) at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine. To determine the efficacy and safety of varenicline for smoking cessation compared with placebo or sustained-release bupropion (bupropion SR). A randomized, double-blind, placebo-controlled trial conducted between June 2003 and March 2005 at 14 research centers with a 12-week treatment period and follow-up of smoking status

JAMA2006

44. Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact

Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact Mayo J L, Cahill G M, Lott R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of a single dose of sustained-release bupropion 200 mg (GlaxoSmithKline) versus a single dose of immediate-release bupropion 150 mg (generic). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients from the authors

NHS Economic Evaluation Database.2005

45. Review: nortriptyline and bupropion each increase smoking cessation rates

Review: nortriptyline and bupropion each increase smoking cessation rates Review: nortriptyline and bupropion each increase smoking cessation rates | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: nortriptyline and bupropion each increase smoking cessation rates Article Text Therapeutics Review: nortriptyline and bupropion each increase smoking cessation rates Free Charles J Bentz , MD, FACP Statistics from Altmetric.com No Altmetric data available for this article. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation

Evidence-Based Medicine (Requires free registration)2005

46. Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR

Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR Are there gender differences in smoking cessation, with and without bupropion: pooled- and meta-analyses of clinical trials of Bupropion SR Scharf D, Shiffman S CRD summary This review found that Bupropion SR (...) is an effective smoking cessation aid for both men and women. However, women have less success at quitting than men, regardless of whether treated with Bupropion SR or placebo. Given that the quality of the original studies was not assessed, a limited search was employed and the review methods were not reported, the reliability of the authors' conclusions is weakened considerably. Authors' objectives To examine gender differences in smoking cessation with and without treatment with Bupropion SR. Searching

DARE.2004

47. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. 12132977 2002 07 22 2002 07 30 2016 10 17 0098-7484 288 4 2002 Jul 24-31 JAMA JAMA Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. 468-74 African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite (...) a different profile of both smoking and quitting patterns. To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans. Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals

JAMA2002

48. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation Woolacott (...) N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Hyde C J, Barton P M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Woolacott N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Hyde C J, Barton P M. The clinical effectiveness and cost-effectiveness of bupropion

Health Technology Assessment (HTA) Database.2002

49. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation

Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 39. 2002 Authors' objectives To provide guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Authors' conclusions Guidance 1.1 Nicotine replacement therapy (NRT) and bupropion are recommended for smokers who have expressed

Health Technology Assessment (HTA) Database.2002

50. Cardiotoxicity following bupropion overdose

Cardiotoxicity following bupropion overdose Cardiotoxicity following bupropion overdose Cardiotoxicity following bupropion overdose Druteika D, Zed P J Authors' objectives To determine whether an overdose of bupropion has been associated with cardiotoxicity. Searching MEDLINE (from 1966 to January 2002), EMBASE (from 1980 to January 2002), Current Contents (January 2002) and PubMed (January 2002) were searched. The keywords used in the search included 'bupropion', 'overdose (drug (...) )', 'intoxication', 'poisoning' and 'acute ingestion'. The reference lists from identified studies and reviews were also examined. Only studies published in the English language were included. Study selection Study designs of evaluations included in the review Studies of any design were eligible for inclusion. The included studies were retrospective case series (cases reported to six U.S. poison centres between 1989 and 1991) and case reports. Specific interventions included in the review Studies of bupropion

DARE.2002

51. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation Woolacott (...) N F, Jones L, Forbes C A, Mather L C, Sowden A J, Song F J, Raftery J P, Aveyard P N, Barton P M Authors' objectives To assess the clinical effectiveness, cost-effectiveness and adverse events of bupropion sustained-release (BSR) and nicotine replacement therapy (NRT) for smoking cessation. Searching The authors searched a number of different databases and websites up to May 2001 (a detailed search strategy was provided). The bibliographies of retrieved articles and submissions were also checked

DARE.2002

52. Bupropion (Zyban) in smoking cessation

Bupropion (Zyban) in smoking cessation Bupropion (Zyban) in smoking cessation We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Bupropion (Zyban) in smoking cessation Share: Reading time approx. 5 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version: 2 Technology (...) and target group Bupropion (Zyban), the first drug registered for smoking cessation that does not contain nicotine, was introduced in Sweden during 2000. Originally, bupropion is an antidepressant. It is a prescription drug, but not covered under the drug benefit. The target group for treatment with bupropion includes smokers who have not succeeded with other treatment methods for smoking cessation. Patient benefit The effects of bupropion, in combination with individual support, have been studied

Swedish Council on Technology Assessement2002

53. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

NIHR HTA programme2002

54. New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®)

New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin | Therapeutics Initiative Independent Healthcare Evidence > > [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin Mirtazapine (Remeron ® ) Approved indication: “Symptomatic

Therapeutics Letter2000

55. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation

Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Nielsen K, Fiore M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sustained-release bupropion, nicotine patch, or both for smoking cessation. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of smokers who were enrolled on a smoking cessation programme, the details of which were reported in a study published in 1999. Setting The study setting

NHS Economic Evaluation Database.2000

56. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs

Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Halpern M T, Khan Z M, Young T L, Battista C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sustained-release (SR) bupropion hydrochloride in health plan and work site smoking-cessation programmes. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 100,000 employees

NHS Economic Evaluation Database.2000

58. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. 10053177 1999 03 04 1999 03 04 2015 11 19 0028-4793 340 9 1999 Mar 04 The New England journal of medicine N. Engl. J. Med. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. 685-91 Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained (...) -release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo

NEJM1999

59. A comparison of sustained-release bupropion and placebo for smoking cessation.

A comparison of sustained-release bupropion and placebo for smoking cessation. 9337378 1997 10 23 1997 10 23 2015 11 19 0028-4793 337 17 1997 Oct 23 The New England journal of medicine N. Engl. J. Med. A comparison of sustained-release bupropion and placebo for smoking cessation. 1195-202 Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We (...) excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or "target quit date") was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air

NEJM1997